Business Wire

YAMAHA

Share
Yamaha: Japanese-style Music Education Using Recorders Begins at Public Primary Schools in India

In cooperation with the Delhi Board of School Education, Yamaha Corporation (below, "Yamaha") introduced Japanese-style instrumental music education using recorders for grade V students at ten public primary schools in India in April. Programs using recorders and keyboards have been offered as extra-curriculum activities at private primary schools in India since 2017, but this is the first time a program will be offered as part of public primary school classes. The program offered by Yamaha not only includes technical recorder instruction, but also incorporates groupwork and discussion within classes to cultivate mutual understanding. Preceding the start of the classes, music teacher training is being conducted with an emphasis on using a holistic learning approach. Yamaha aims to expand the program to more schools in Delhi in the future. “Introduction of Japanese-style music education in primary education in India” was adopted by MEXT as a 2022 EDU-Port Japan*1 Supported Project.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230511005424/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Classes at public primary school in India

About School Project

As a comprehensive musical instruments manufacturer, Yamaha has been promoting the advantages of music and instrumental music education to music education sites around the world. In particular, Yamaha’s School Project, which it has been developing principally in emerging countries since 2015, is an initiative with the aim of popularizing activities using music and musical instruments in public education to convey the joy of music and musical instruments. To date, Yamaha has provided a total of 2,020,000 children (as of March 2023) in seven countries—Malaysia, Indonesia, Vietnam, India, Brazil, the United Arab Emirates, and Egypt—with opportunities to learn instrumental music, helping to create an environment where children can enjoy music and playing musical instruments.

Through this activity, Yamaha aims to contribute to Goal 4: "Quality Education," Goal 10: “Reduced Inequalities,” Goal 16: “Peace, Justice and Strong Institutions,” and Goal 17: "Partnerships for the Goals" of the Sustainable Development Goals (SDGs), as well as to develop children's non-cognitive skills through music and instrumental music education and to formulate a business model for musical education activities tailored to the educational situation in schools around the world.

Comments from Yasuhiro Yonehara, First Secretary, Embassy of Japan in India

Walking through the streets of India, one can hear music along with the bustling of the city. In Bollywood films, actors can be seen dancing joyfully to upbeat songs. Indian people are very familiar with music, and I feel that music is an integral part of their lives. How exciting it is when Indian children pick up a recorder, an unfamiliar instrument, learn to play it and create music. I sincerely wish that this initiative, which is making this possible, will be a huge success.

*1 EDU-Port Japan is a “public-private, nationwide” initiative to introduce Japanese-style education overseas using the public-private collaborative platform, supported by Japan’s Ministry of Education, Culture, Sports, Science and Technology (MEXT).

https://www.yamaha.com/en/about/activities/school_project/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005424/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium4.11.2025 13:00:00 CET | Press release

New data from the ongoing FLEX Study highlight the value of real-world evidence in personalizing chemotherapy decisions and improving outcomes in early-stage breast cancer Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new results from the ongoing real-world FLEX Study (NCT03053193) at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12 in San Antonio, Texas. The company will present five posters, led by Agendia investigators and independent academic collaborators, that collectively highlight the broad clinical impact of MammaPrint® + BluePrint® genomic profiling in optimizing treatment decisions and improving outcomes for patients with hormone receptor positive, HER2-negative (HR+/HER2–) early breast cancer (EBC). “We look forward to sharing these new findings from the FLEX Study, which spans more than 20,000 participants across 100 global sites, making it the largest and most diverse real-world evidence c

Nature Communications Study Supports HER2DX as a Genomic Tool for Tailored Therapy in Older Individuals With HER2+ Breast Cancer4.11.2025 13:00:00 CET | Press release

First study to evaluate HER2DX in a randomized trial focused exclusively on older individuals (aged 70–80 years). HER2DX independently predicts long-term survival outcomes in patients treated with trastuzumab with or without chemotherapy. Findings support HER2DX as a tool to guide chemotherapy decisions and de-escalation strategies in older adults. REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company seeking to revolutionize precision oncology through biomarker innovation, today announced the publication of the study “HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy” in Nature Communications. This landmark study evaluated the HER2DX genomic assay in 154 individuals aged 70–80 years enrolled in the RESPECT trial (NCT01104935), a randomized phase III study comparing adjuvant trastuzumab with or without chemotherapy. The analysis, known as Trans-RESPECT, is the first to evaluate HER2DX in an

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months4.11.2025 12:30:00 CET | Press release

Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in TRD, including potential rolling submissionCompany now plans to disclose 9-week data (Part A) from COMP006 together with 26-week data (Part B) from COMP005 in Q1 2026Disclosure of 26-week (Part B) COMP006 data expected in early Q3 2026Cash position of $185.9 million as of September 30, 2025Conference call on November 4 at 8 am ET (1 pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2025 and provided an update on recent progress across its business. “With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch timing for COMP360 in TRD by 9-12 mont

TELEO Capital Closes Oversubscribed TELEO Capital II at $350 Million Hard Cap4.11.2025 12:00:00 CET | Press release

TELEO Capital Management, LLC (“TELEO”), an operationally focused private equity firm focused on investing in lower middle market enterprise software companies, today announced the final close of TELEO Capital II (“Fund II”) at its hard cap of $350 million in Limited Partner capital commitments. Fund II was oversubscribed and attracted a diverse group of new and existing institutional investors. TELEO executes a time-tested strategy in the lower middle market, leveraging a large purpose-built team and repeatable process designed to deliver consistent, outsized returns. Fund II will continue TELEO’s focus on acquiring mission-critical software divisions of large corporations. TELEO is an ideal partner to large corporate sellers in need of a solution where speed and certainty to close, minimal post-closing distraction risk from shared services agreements, and a commitment to protecting customer and employee relationships are extremely important. “We are honored by the trust our investors

Celonis Unveils Platform Innovations to Power the AI-Driven, Composable Enterprise4.11.2025 11:00:00 CET | Press release

Celonis, a global leader in Process Intelligence, today at Celosphere 2025 announced major platform innovations that power enterprise AI to reinvent and continuously improve business operations. Daniel Brown, Chief Product Officer at Celonis, emphasized the need for a structured approach to agentic AI. “To truly operationalize AI, you need to identify the right use cases, redesign your business processes, and orchestrate the agents alongside your people and existing systems," Brown said. "Our enhanced capabilities empower our customers and their partners to build AI solutions that lift their operations to unprecedented levels of efficiency and agility.” The Celonis Process Intelligence Platform extracts raw data from systems, applications and devices within and across enterprises. It enriches this data with customers’ unique business context to create a living digital twin of operations—the Process Intelligence Graph. On top of the Graph, the Process Intelligence Platform provides the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye